Phinomics

From Invisible Biology to Tomorrow’s Therapeutics

health AI / biotech / medtech

StageSeed / Incubator/Accelerator

Employees9

LocationSan Carlos, CA

About

Phinomics is unlocking a hidden layer of biology—circular DNA and cryptic proteins—to power the next generation of AI in precision medicine. While others models train on a static, 1-D linear genome, we see a 3D, dynamic ecosystem of disease-driving elements. Our platform decodes and quantifies these overlooked signals and integrates them into high-resolution, multimodal maps of disease biology—connecting circular DNA with expression, epigenetics, and clinical outcomes. But the real breakthrough isn’t just better data—it’s what we do with it. Phinomics trains AI on orthogonal, causal, and clinically validated signals that go far beyond conventional inputs. The result is biological intelligence that understands disease from the inside out, powering new models for prediction, precision, and cure. That’s Phinomics. The lens into biology no one else has and the data engine that will power the future of precision medicine.

Product

Value proposition: Phinomics provides a first-in-class Circulome data layer and multi-omic integration to reveal causal mechanisms in cancer biology, enabling targeted therapeutic discovery and patient stratification.
Target customers: pharma/biotech companies, research institutions, CROs

Founders

Stephen Levene — Co-Founder
Massa Shoura — Co-Founder

Products

Circulome data layermulti-omic integration platformmatched normal tissue blueprintcausal multi-omic knowledge graph

Key features

Circulome with extrachromosomal circular DNA at high resolutiontrue matched multi-modal integration from the same patientmatched normal tissue samples for tumor-specific signalcausal mechanism discovery across genomic, transcriptomic, epigenomic, proteomic layersbiomarker discovery and patient stratificationdefensible IP grounded in mechanistic biology

Technologies

circulome sequencingmulti-omic integrationknowledge graphsmatched normal tissue profilingbiomarker discoverycausal inference

Target conditions

canceroncologytumor evolutiondrug resistance

Competitors

Roundhill BioGuardant Health (in the context of liquid biopsy and multi-omics)BI/ONGenialisAdaptive Biotechnologies

Investors

K5 GlobalNational Institutes of Health (HHS)Creative Destruction LabSpringboard Health AngelsEndless Frontier LabsSilicon Catalyst AngelsChipStart UK

News

Phinomics - 2026 Company Profile, Team, Funding & Competitors · 2026-05-21T00:00:00.000Z
Beyond the Double Helix: Phinomics Joins "All Access hosted by Andy Garcia" to Explore Hidden Frontiers in Genetics · 2026-06-12T07:00:00.000Z
New insights into eccDNA could revolutionise cancer understanding and explainable AI in genomics | Noah News · 2026-06-12T07:59:18.000Z
Guido Mathews' Post - LinkedIn · 2026-06-09T00:00:00.000Z
PMWC 2026 | Precision Medicine World Conference, March 4–6 · 2026-01-28T00:00:00.000Z

Browse similar startups

Related startups

Physera — San Francisco, CA
PhyxUp Health — San Francisco, CA
PointHealth AI — San Francisco, CA
Precision AI Solutions — Foster City, CA
PRIMA HEART, A MEDICAL GROUP — Pinedale, CA
PriMi Health — San Francisco, CA
Response Pharmaceuticals — Mclean, VA
Riboway Therapeutics — Cambridge, MA
Sarcomatrix — Reno, NV
Senvera Therapeutics, Inc. A Curie.Bio Company — Boston, MA
Stipple Bio — Cambridge, MA
Symbiome — San Francisco, CA

Profile updated Jul 29, 2026. Sources: phinomics.com